The treatment strategy of acute promyelocytic leukemia The treatment of acute promyelocytic leukemia is divided into three phases: Phase I, induction chemotherapy Generally, chemotherapy with retinoic acid or arsenic trioxide plus DA regimen is applied, which usually leads to complete remission in one course of treatment. After the bone marrow is in remission, the patient enters consolidation therapy. The second stage, consolidation therapy, is usually alternated with arsenic trioxide, retinoic acid, DA (or IA) regimen, and high-dose cytarabine chemotherapy, with a consolidation period of about six months to a year. After about six to eight courses of treatment, the bone marrow and PML/RARA fusion gene will be evaluated, and if the fusion gene turns negative by PCR, the treatment can be transferred to maintenance treatment. After about six months, if all tests are good, the drug can be stopped for observation. Although the drug is discontinued, the fusion gene should be checked every six months, and after about three years, there is still no relapse. Then you can check it once a year. In your case, it depends on what regimen has been used. You must have used arsenic trioxide, high-dose cytarabine, DA (or IA) regimen. If used, you can enter the oral maintenance period. Patient: Description of the condition (onset time, main symptoms, hospital visited, etc.): On June 19, 2010, an abnormally low white blood cell (700) was routinely detected, and after hospitalization, periodontal bleeding was observed, and the patient is now seen at Guangxi Guilin Medical College. Do I need to do chemotherapy again?